You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 297 No. 3, January 17, 2007 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Coagulation Disorders
 •Men's Health, Other
 •Venous Thromboembolism
 •Adverse Effects
 •Alert me on articles by topic

Fixed-Dose Unfractionated Heparin vs Low-Molecular-Weight Heparin for Venous Thromboembolism

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Kearon and colleagues1 compared the use of fixed-dose, weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute venous thromboembolism (VTE). One of the key findings was the small risk of major bleeding at 10 days, although there was a non–statistically significant difference at 3 months (1.7% for the unfractionated heparin group vs 3.4% for the low-molecular-weight heparin group).

We believe that the definitions of bleeding are too heterogeneous and that further clarification of the underlying etiology of the bleeding is required. In this study, bleeding was defined as major if it was clinically overt and associated with a decrease in hemoglobin level of at least 2.0 g/dL, involved a need for transfusion of 2 or more units of red blood cells, or involved a critical site (eg, retroperitoneal, intracranial). These are less stringent criteria than the TIMI classification,2 which requires a decrease in hemoglobin of more than . . . [Full Text of this Article]

Neeraj Bhala, MRCP
nijbhala@doctors.org.uk

Ashit Shah, MRCP; Andrew King, MRCP; Chakri Molugu, MRCP
Department of Gastroenterology
University Hospital of Coventry & Warwick
Walsgrave, Coventry, England


RELATED LETTERS

Fixed-Dose Unfractionated Heparin vs Low-Molecular-Weight Heparin for Venous Thromboembolism
Huichun Zhan and Haoyi Zheng
JAMA. 2007;297(3):261-262.
EXTRACT | FULL TEXT  

Fixed-Dose Unfractionated Heparin vs Low-Molecular-Weight Heparin for Venous Thromboembolism
Jonathan Lee Edwards
JAMA. 2007;297(3):262.
EXTRACT | FULL TEXT  

Fixed-Dose Unfractionated Heparin vs Low-Molecular-Weight Heparin for Venous Thromboembolism
Darrell W. Harrington and Ayad Jindeel
JAMA. 2007;297(3):262.
EXTRACT | FULL TEXT  

Fixed-Dose Unfractionated Heparin vs Low-Molecular-Weight Heparin for Venous Thromboembolism—Reply
Clive Kearon, Jeffrey S. Ginsberg, Jim A. Julian, Michael Gent, and for the Fixed-Dose Heparin (FIDO) Investigators
JAMA. 2007;297(3):263.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Comparison of Fixed-Dose Weight-Adjusted Unfractionated Heparin and Low-Molecular-Weight Heparin for Acute Treatment of Venous Thromboembolism
Clive Kearon, Jeffrey S. Ginsberg, Jim A. Julian, James Douketis, Susan Solymoss, Paul Ockelford, Sharon Jackson, Alexander G. Turpie, Betsy MacKinnon, Jack Hirsh, Michael Gent, and for the Fixed-Dose Heparin (FIDO) Investigators
JAMA. 2006;296(8):935-942.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.